Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
28 nov. 2023 04h00 HE
|
AKAMPION
Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF Munich, Germany, November 28, 2023 -- Ebenbuild, a company developing personalized, AI-driven...
Ebenbuild erhält öffentliche Förderung im Rahmen des UBIC-Konsortiums für das Projekt "Digital Lung Twin“
28 nov. 2023 04h00 HE
|
AKAMPION
Bundesministerium für Bildung und Forschung (BMBF) bewilligt Fördermittel in Höhe von bis zu 1,8 Millionen Euro München, Deutschland, 28. November 2023 -- Ebenbuild, ein Unternehmen, das...
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
24 nov. 2023 08h55 HE
|
SciSparc Ltd
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels
24 nov. 2023 08h30 HE
|
Safety Shot, Inc.
Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and improving clarityA double-blinded, placebo controlled, clinical trial designed to...
Clinical Trial Supply and Logistics Market Size to Surpass USD 6.44 Billion by 2032
22 nov. 2023 10h15 HE
|
Precedence Research
Ottawa, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The global clinical trial supply and logistics market size accounted for USD 3.42 billion in 2023, According to Precedence Research. North America led the...
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
17 nov. 2023 08h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly...
Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial
14 nov. 2023 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
New demonstration of the predictive power of an in silico clinical trial in oncology
13 nov. 2023 02h00 HE
|
Novadiscovery
New demonstration of the predictive power of an in silico clinical trial in oncology Quantitative Systems Pharmacology (QSP) model of lung cancer and 5,900 digital patients architected to complete...
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
09 nov. 2023 16h05 HE
|
HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
09 nov. 2023 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy